Ivemend

Fosaprepitant, the active ingredient in Ivemend, is a NK1 receptor antagonist presented as a 150 mg lyophilized powder for solution for injection for intravenous use. It treats prevention of acute and delayed nausea and vomiting associated with highly and moderately emetogenic chemotherapy in cancer patients.

GNH USA supplies Ivemend as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide.

Ivemend (fosaprepitant) is used in the management of chemotherapy‑induced nausea and vomiting, a condition mediated by substance P acting on NK1 receptors.

- Highly emetogenic chemotherapy: prevents acute and delayed nausea and vomiting. - Moderately emetogenic chemotherapy: prevents acute and delayed nausea and vomiting. - Combination antiemetic therapy: used with a 5‑HT3 antagonist and dexamethasone to enhance control of chemotherapy‑induced nausea and vomiting.

Fosaprepitant may be associated with a range of adverse reactions, most of which are mild to moderate in severity.

Common Side Effects: - Headache: mild to moderate intensity. - Fatigue: transient feeling of tiredness. - Constipation: reduced bowel movements. - Injection site reactions: erythema or discomfort at the infusion site.

Serious or Rare Side Effects: - Hypersensitivity reactions: including rash, pruritus, or anaphylaxis. - Elevated liver enzymes: increased ALT or AST levels. - Cardiac arrhythmias: rare cases of QT prolongation.

When using Ivemend, several safety considerations should be observed.

- Assess renal function: dose adjustment may be needed in severe renal impairment. - Monitor hepatic function: use with caution in patients with liver disease. - Avoid concomitant use with strong CYP3A4 inhibitors: may increase fosaprepitant exposure. - Use caution in patients receiving other QT‑prolonging agents: monitor ECG. - Pregnancy: safety not established; avoid unless benefit outweighs risk. - Store at 2‑8 °C: keep refrigerated, protect from light, do not freeze or shake.

Fosaprepitant can interact with several drug classes, requiring attention to avoid reduced efficacy or increased toxicity.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): can markedly increase fosaprepitant plasma levels. - Concomitant use with other NK1 antagonists: may lead to additive toxicity.

Moderate Interactions (Monitor Closely): - Moderate CYP3A4 inducers (e.g., rifampin, carbamazepine): may reduce efficacy of fosaprepitant. - 5‑HT3 antagonists and dexamethasone: may require dose adjustment of dexamethasone due to CYP3A4 interaction. - Drugs that prolong QT interval: co‑administration may increase risk of cardiac arrhythmias.